公开(公告)号：US20240217957A1

公开(公告)日：2024-07-04

申请号：US18522917

申请日：2023-11-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Asato KINA ,  Zenichi IKEDA ,  Mitsunori KONO ,  Yuya OGURO ,  Osamu KUBO ,  Toru YAMASHITA ,  Kazuaki TAKAMI ,  Takafumi YUKAWA ,  Masaki SETO ,  Makoto KAMATA ,  Kenjiro SATO ,  Masataka MURAKAMI ,  Yusuke SASAKI ,  Matthew Thomas REYNOLDS ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Takuto KOJIMA ,  Keiko KAKEGAWA ,  Florian PÜNNER ,  Shinji NAKAMURA ,  Nao MORISHITA ,  Tadashi HIDAKA ,  Sachie TAKASHIMA ,  Takahiko TANIGUCHI

IPC: C07D413/04 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61P25/00 ,  C07D413/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20170129887A1

公开(公告)日：2017-05-11

申请号：US15264213

申请日：2016-09-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi MIKAMI ,  Shinji NAKAMURA ,  Tomoko ASHIZAWA ,  Shigekazu SASAKI ,  Takahiko TANIGUCHI ,  Izumi NOMURA ,  Masanori KAWASAKI

IPC: C07D471/04 ,  A61K31/555 ,  A61K31/498 ,  A61K9/20 ,  C07F7/18

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20160264536A1

公开(公告)日：2016-09-15

申请号：US15031505

申请日：2014-10-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki SETO ,  Yoshihiro BANNO ,  Toshihiro IMAEDA ,  Yuichi KAJITA ,  Tomoko ASHIZAWA ,  Masanori KAWASAKI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Izumi NOMURA ,  Takahiko TANIGUCHI ,  Shogo MARUI

IPC: C07D277/56 ,  C07D403/12 ,  C07D239/28 ,  C07D403/04 ,  C07D239/47 ,  C07D239/36 ,  C07D239/52 ,  C07D241/24 ,  C07D498/08 ,  C07D413/04 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D409/04 ,  C07D401/12 ,  C07D239/42

CPC classification number: C07D277/56 ,  C07D239/28 ,  C07D239/36 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/56 ,  C07D241/24 ,  C07D241/26 ,  C07D277/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D498/04 ,  C07D498/08

Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20150099757A1

公开(公告)日：2015-04-09

申请号：US14517313

申请日：2014-10-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Akira KAWADA ,  Mitsuyo KONDO ,  John F. QUINN ,  Jun KUNITOMO ,  Masato YOSHIKAWA ,  Makoto FUSHIMI

IPC: C07D403/14 ,  C07D413/14

CPC classification number: C07D403/04 ,  A61K9/2059 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症等的药物。 式（I0）的化合物：其中R1表示取代基，R2表示氢原子或取代基，R3表示氢原子或取代基，环A表示可被取代的芳香环，环B表示 可被取代的5元杂芳环或其盐。

公开(公告)号：US20130303553A1

公开(公告)日：2013-11-14

申请号：US13944370

申请日：2013-07-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI

IPC: C07D471/04 ,  C07D473/00 ,  C07D498/04

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。

公开(公告)号：US20170233339A1

公开(公告)日：2017-08-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Takahiko TANIGUCHI ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D207/08

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20170114044A1

公开(公告)日：2017-04-27

申请号：US15377149

申请日：2016-12-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Akira KAWADA ,  Mitsuyo KONDO ,  John F. QUINN ,  Jun KUNITOMO ,  Masato YOSHIKAWA ,  Makoto FUSHIMI

IPC: C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D409/14 ,  C07D409/04 ,  C07D405/14 ,  C07D413/14 ,  C07D401/14 ,  C07D405/04

CPC classification number: C07D403/04 ,  A61K9/2059 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.A compound of formula (I0) wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

公开(公告)号：US20140228320A1

公开(公告)日：2014-08-14

申请号：US14253139

申请日：2014-04-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI ,  John F. QUINN ,  Joseph RAKER ,  Fatoumata CAMARA ,  Yi WANG

IPC: C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07F7/10

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗由式（I）表示的精神分裂症等的药剂：